These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 30536884)

  • 1. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.
    Wu S; Gao L; Cipriani A; Huang Y; Yang Z; Yang J; Yu S; Zhang Y; Chai S; Zhang Z; Sun F; Zhan S
    Diabetes Obes Metab; 2019 Apr; 21(4):975-983. PubMed ID: 30536884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.
    Xu L; Yu SQ; Gao L; Huang Y; Wu SS; Yang J; Sun YX; Yang ZR; Chai SB; Zhang Y; Ji LN; Sun F; Zhan SY
    Biomed Environ Sci; 2020 Jan; 33(1):37-47. PubMed ID: 32029057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
    Lyu X; Zhu X; Zhao B; Du L; Chen D; Wang C; Liu G; Ran X
    Sci Rep; 2017 Mar; 7():44865. PubMed ID: 28322294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
    Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
    Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Gao L; Yu S; Cipriani A; Wu S; Huang Y; Zhang Z; Yang J; Sun Y; Yang Z; Chai S; Zhang Y; Ji L; Zhan S; Sun F
    Aging Dis; 2019 Dec; 10(6):1311-1319. PubMed ID: 31788342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
    Chai S; Niu Y; Liu F; Wu S; Yang Z; Sun F
    J Diabetes Res; 2024; 2024():8145388. PubMed ID: 39072050
    [No Abstract]   [Full Text] [Related]  

  • 12. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Deacon CF
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
    Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
    Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
    Cai X; Yang W; Zhou L; Zhang S; Han X; Ji L
    Endocrine; 2015 Dec; 50(3):590-7. PubMed ID: 26048437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Luo Y; Lu K; Liu G; Wang J; Laurent I; Zhou X
    Clin Drug Investig; 2018 Dec; 38(12):1089-1108. PubMed ID: 30255388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y; Tsoi MF; Cheung BMY
    Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.